Simplifying Progress
Conference call Nine-month 2020 results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech
October 20, 2020
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.
Throughout this presentation, differences may be apparent as a result of rounding during addition.
2
Highlights
- Sales revenue, order intake and earnings with significant double-digit growth rates
- Bioprocess Solutions Division: Expands dynamically; with strong overall momentum and additional pandemic-related orders
- Lab Products & Services Division: Recovery effects in Q3 after difficult first six months
- Acquisitions with very positive development
- BIA Separations to become part of Sartorius Stedim Biotech; transaction expected to close in Q4/2020
- Outlook for 2020 specified and slightly increased; uncertainty remains
3
Agenda
Sartorius Group
9M 2020 results | FY 2020 guidance
Sartorius Stedim Biotech Group
9M 2020 results | FY 2020 guidance
Questions & Answers
4
Strong profitable growth
Sartorius Group | 9M 2019 | 9M 2020 | in % | in % cc1 |
in millions of € unless otherwise specified | ||||
Sales revenue | 1,355.8 | 1,680.0 | +23.9 | +25.2 |
Order intake | 1,435.0 | 1,956.5 | +36.3 | +37.8 |
Underlying EBITDA2 | 361.1 | 488.7 | +35.3 | |
Underlying EBITDA2 margin in % | 26.6 | 29.1 | +2.5pp | |
Underlying EPS3 (ord.) in € | 2.23 | 3.08 | +38.0 | |
Underlying EPS3 (pref.)in € | 2.24 | 3.09 | +37.8 |
- Acquisitions contribute close to +6pp to sales growth; net effect from pandemic approx. +6pp / approx. +10pp for order intake
- Underlying EBITDA margin driven by economies of scale and lower costs in some areas due to pandemic; acquisitions with no relevant effects; dilutive effect from currencies of about half a percentage point
1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and tax rate
5
Double-digit sales growth in all geographies
Americas
- in millions
+28.7% |
586.0 |
461.7 |
9M 2019 9M 2020 |
EMEA
- in millions
+23.6% |
672.6 |
546.1 |
9M 2019 9M 2020 |
Asia|Pacific | Sales by Region |
€ in millions | in % |
+23.3% | ||
EMEA | ||
~ 40% | Americas | |
421.5 | ~ 35% | |
348.1 | ||
€1,680.0m | ||
Asia|Pacific | ||
9M 2019 9M 2020 | ~ 25% |
- Americas: strong organic growth for BPS; LPS supported by acquisitions and with positive trend in Q3
- EMEA: BPS with strong performance; solid performance of LPS considering economic challenges
- Asia|Pacific: BPS with the highest order momentum; LPS demand further improved after lockdown lifted in China
Acc. to customers' location; growth in constant currencies
6
BPS: High growth across all product segments and regions
Order Intake
- in millions
+44.2% cc
+42.7% | |
1,546.8 | |
1,084.0 | |
9M 20191 | 9M 2020 |
Sales Revenue
- in millions
+29.0% cc
+27.7% | |
1,009.0 | 1,288.1 |
9M 20191 | 9M 2020 |
Underlying EBITDA & Margin
- in millions
+41.3%
410.5 | |
290.5 | |
28.8% | 31.9% |
9M 20191 | 9M 2020 |
- Strong organic growth; pandemic-driven effects presumably around 10pp (approx. half of that from demand related to coronavirus vaccines and therapeutics and other half from inventory build-up), acquisitions accounted for approx. 4pp of growth
- Pandemic-driveneffects estimated at around 15pp of order intake growth
- Underlying EBITDA margin rose due to economies of scale, despite slight FX dilution
1 9M 2019 figures reported: Order intake €1,100.0m, sales €1,025.0m, underlying EBITDA €300.6m
7
LPS: Robust sales development
Order Intake
- in millions
+18.1% cc
+16.7% | |
351.0 | 409.7 |
9M 20191 | 9M 2020 |
Sales Revenue
- in millions
+14.2% cc +13.0%
346.8 | 391.9 |
9M 20191 | 9M 2020 |
Underlying EBITDA & Margin
- in millions
+10.8%
70.6 | 78.2 |
20.4% | 20.0% |
9M 20191 | 9M 2020 |
- Recovery effects in Q3 and positive development of bioanalytics after a difficult first half due to pandemic
- Acquisitions contribute around 12pp to sales growth; net effect from pandemic more than -3pp
- Underlying EBITDA margin influenced by approx. half a percentage point dilutive FX effect
1 9M 2019 figures reported: Order intake €335.0m, sales €330.8m, underlying EBITDA €60.5m
8
Operating cash flow increases significantly
Sartorius Group | 9M 2019 | 9M 2020 | in % |
in millions of € unless otherwise specified | |||
Underlying EBITDA | 361.1 | 488.7 | +35.3 |
Extraordinary items | -18.5 | -30.4 | n.m. |
Financial result | -17.9 | -28.3 | n.m. |
Underlying net profit1,2 | 153.2 | 211.2 | +37.9 |
Reported net profit2 | 121.3 | 149.1 | +22.9 |
Operating cash flow | 254.1 | 380.0 | +49.6 |
Investing cash flow3 | -175.6 | -911.0 | n.m. |
CAPEX ratio (in %) | 12.5 | 8.0 | -4.5pp |
- Net operating cash flow mostly driven by higher earnings and factoring program (~€97m)
- Extraordinary items influenced by M&A
- Investing cash flow includes acquisition of Danaher portfolio in Q2
- Tax rate at 30% (+3pp vs. PY) due to accounting of tax risks, not cash-effective in 9M
1 Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate 2 After non-controlling interest 3 Net cash flow from investing activities and acquisitions
9
Financial indicators remain on very solid level
Key Financial Indicators
Sartorius Group | Dec. 31, | Sep. 30, |
2019 | 2020 | |
Equity ratio in % | 38.1 | 29.2 |
Net debt in millions of € | 1,014.0 | 1,610.3 |
Net debt | underlying | 2.0 | 2.5 |
EBITDA | ||
- Balance sheet and equity ratio influenced by the recent acquisitions and higher cash position
Net Debt and Net Debt to Underlying EBITDA
2,000 | 4.0 |
1,500 | 3.0 |
1,000 | 2.0 |
500 | 1.0 |
0 | 0.0 |
Q1-Q4Q1-Q4Q1-Q4Q1-Q4Q1-Q4Q1-Q4Q1-Q3
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Net debt in millions of € (lhs) | Net debt to underlying EBITDA (rhs) | |||||
10
Outlook for 2020 specified and slightly increased; uncertainty remains
FY 2020 Guidance1 | Sales revenue growth | Underlying EBITDA margin | ||
previous | change / new | previous | change / new | |
Sartorius Group | ~ 22% - 26% | upper end or slightly above | ~ 28.5% | + 1 pp → ~ 29.5% |
~ 22% - 26% | ||||
- thereof acquisitions | ~6.5pp | ~6.5pp | slightly dilutive | neutral |
Bioprocess Solutions | ~ 26% - 30% | upper end or slightly above | ~ 31.0% | + 1 pp → ~ 32.0% |
~ 26% - 30% | ||||
- thereof acquisitions | ~4.5pp | ~4.5pp | slightly dilutive | neutral |
Lab Products & Services | ~ 10% - 14% | upper end or slightly above | ~ 20.0% | + 1 pp → ~ 21.0% |
~ 10% - 14% | ||||
- thereof acquisitions | ~12.5pp | slightly above ~12.5pp | slightly accretive | slightly accretive |
- CAPEX ratio ~10% (unchanged); net debt to underlying EBITDA remains projected slightly below ~2.75
- Acquisition of Biological Industries included for 12 months; life science portfolio from Danaher included for approx. 8 months; closing of the acquisition of BIA Separations expected before year end
- Guidance based on the assumption that logistics chains continue to be stable and production lines remain in operation
1 In constant currencies
11
Agenda
Sartorius Group
9M 2020 results | FY 2020 guidance
Sartorius Stedim Biotech Group
9M 2020 results | FY 2020 guidance
Questions & Answers
12
Sartorius Stedim Biotech Group
BIA Separations to become part of Sartorius Stedim Biotech
Strategic rationale
Acquisition terms and financials
Closing and consolidation
- Market-leadingtechnology for purification in advanced therapy processes
- Highly complementary to current purification offering and to advanced therapy portfolio
- Transaction volume of €360mn; €240mn in cash, €120mn in SSB shares
- Performance-basedearn-out payments over the next five years
- ~€25mn sales revenue in 2020, very strong double-digit growth rates; margin accretive
- Expected to close in Q4/2020; subject to customary closing conditions
- No material impact on P&L in 2020
13
Sartorius Stedim Biotech Group
Bioprocessing innovator, addressing bottlenecks in advanced therapies
Ajdovščina, Slovenia
~120 employees
Quadrupling production capacity till end 2021
Portfolio
- Pre-packedmonolithic columns optimized for purification in advanced therapy processes (e.g. viruses, plasmids, exosomes)
- Provides significantly higher yield by avoiding shearing effects which occur in traditional purification processes, e.g. in chromatography
Positioning
- Monoliths already used in production of first commercialized advanced therapeutics
- Strong presence in (pre-) clinical projects
Monolithic columns
14
Sartorius Stedim Biotech Group
High growth across all product segments
Sartorius Stedim Biotech Group | 9M 2019 | 9M 2020 | in % | in % cc1 |
in millions of € unless otherwise specified | ||||
Sales revenue | 1,076.7 | 1,379.4 | +28.1 | +29.2 |
Order intake | 1,147.1 | 1,637.9 | +42.8 | +43.9 |
Underlying EBITDA2 | 312.3 | 434.7 | +39.2 | |
Underlying EBITDA2 margin in % | 29.0 | 31.5 | +2.5pp | |
Underlying EPS3 in € | 2.15 | 3.02 | +40.4 |
- Strong organic growth; pandemic-driven effects presumably around 9pp (approx. half of that from demand related to coronavirus vaccines and therapeutics and other half from inventory build-up), acquisitions accounted for approx. 4pp of growth
- Pandemic-driveneffects estimated at around 14pp of order intake growth
- Underl. EBITDA margin rose due to economies of scale and lower costs in some areas due to pandemic; slight FX dilution
1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and tax rate
15
Sartorius Stedim Biotech Group
Double-digit sales growth in all geographies
Americas
- in millions
+29.9% |
484.3 |
375.3 |
9M 2019 9M 2020 |
EMEA
- in millions
+26.6% |
550.5 |
435.9 |
9M 2019 9M 2020 |
Asia|Pacific | Sales by Region |
€ in millions | in % |
+32.3% | EMEA | |
~40% | Americas | |
~35% | ||
344.7 | €1,379.4m | |
265.5 | ||
Asia|Pacific | ||
9M 2019 9M 2020 | ~25% | |
- All regions with strong organic development; Asia|Pacific with the highest order momentum
Acc. to customers' location; growth in constant currencies
16
Sartorius Stedim Biotech Group
Operating cash flow rises significantly
Sartorius Stedim Biotech Group | 9M 2019 | 9M 2020 | in % |
in millions of € unless otherwise specified | |||
Underlying EBITDA | 312.3 | 434.7 | +39.2 |
Extraordinary items | -11.5 | -12.9 | -11.7 |
Financial result | -6.6 | -13.9 | n.m. |
Underlying net profit1,2 | 198.1 | 278.1 | +40.4 |
Reported net profit2 | 179.5 | 243.6 | +35.7 |
Operating cash flow | 223.9 | 327.3 | +46.2 |
Investing cash flow3 | -102.9 | -336.7 | n.m. |
CAPEX ratio (in %) | 9.1 | 5.6 | -3.5pp |
- Net operating cash flow mostly driven by higher earnings and factoring program (~€87m)
- Extraordinary items influenced by M&A expenses, among others
- Investing cash flow includes acquisition of Danaher portfolio in Q2
- Tax rate at 27.5% (+1.5pp vs. PY) due to accounting of tax risks, not cash-effective in 9M
1 Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate 2 After non-controlling interest 3 Net cash flow from investing activities and acquisitions
17
Sartorius Stedim Biotech Group
Financial indicators remain on very solid level
Key Financial Indicators
Sartorius Stedim Biotech | Dec. 31, | Sep. 30, |
2019 | 2020 | |
Equity ratio in % | 64.4 | 58.3 |
Net debt in millions of € | 110.4 | 164.6 |
Net debt | underlying | 0.3 | 0.3 |
EBITDA | ||
- Balance sheet and equity ratio influenced by recent acquisitions and higher cash position
Net Debt and Net Debt to Underlying EBITDA
300 | 1.8 |
250 | 1.5 |
200 | 1.2 |
150 | 0.9 |
100 | 0.6 |
50 | 0.3 |
0 | 0.0 |
Q1-Q4Q1-Q4Q1-Q4Q1-Q4Q1-Q4Q1-Q4Q1-Q3
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Net debt in millions of € (lhs) | Net debt to underlying EBITDA (rhs) | |||||
18
Sartorius Stedim Biotech Group
Outlook for 2020 specified and slightly increased
FY 2020 Guidance1 | Sales revenue growth | Underlying EBITDA margin | ||
previous | change / new | previous | change / new | |
Sartorius Stedim Biotech | ~ 26% - 30% | upper end or slightly above | ~ 31.0% | + 1 pp → ~ 32.0% |
~ 26% - 30% | ||||
- thereof acquisitions | ~5pp | ~5pp | slightly dilutive | neutral |
- CAPEX ratio ~8% (unchanged) net debt to underlying EBITDA projected at slightly below 0.5 (unchanged)
- Acquisition of Biological Industries included for 12 months; life science portfolio from Danaher included for approx. 8 months; closing of the acquisition of BIA Separations expected before year end
- Guidance based on the assumption that logistics chains continue to be stable and production lines remain in operation
1 In constant currencies
19
Questions & Answers
20
Thank you very much for your attention.
21
Attachments
- Original document
- Permalink
Disclaimer
Sartorius AG published this content on 20 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2020 14:29:04 UTC